eISSN: 1644-4124
ISSN: 1426-3912
Central European Journal of Immunology
Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
3/2022
vol. 47
 
Share:
Share:
abstract:
Experimental immunology

Characterization of 5-inflammatory-gene signature to affect the immune status and predict prognosis in breast cancer

Hongyan Zang
1
,
Gaofeng Ni
1
,
Liguo Gong
1

  1. Department of Breast Surgery, Yantaishan Hospital, Yantai, China
Cent Eur J Immunol 2022; 47 (3): 218-233
Online publish date: 2022/11/16
View full text Get citation
 
PlumX metrics:
Introduction
Breast cancer (BC) is associated with an inflammatory microenvironment. In BC, epidemiological evidence suggests that inflammation is associated with a poor prognosis. However, approaches to determine the extent of inflammation in the tumor microenvironment remain unclear.

Material and methods
We downloaded the expression profiles and corresponding clinicopathological information of 1050 BC tissues and 59 cases of normal breast tissue from The Cancer Genome Atlas (TCGA) dataset. Similarly, data of 1050 BC tissues were downloaded from Gene Expression Omnibus (GEO) and 200 inflammation-related genes were downloaded from the MSigDB database. We developed an inflammatory risk model to reflect the immune microenvironment in BC.

Results
Multivariate Cox analysis showed that the risk score was an independent predictor of overall survival (OS). Inflammatory signature was significantly associated with clinical and molecular features and could serve as an independent prognostic factor for BC patients. Furthermore, most immune cells were significantly less infiltrated in the high-risk group than in the low-risk group. There was a significant difference in survival time between the group with a high and low tumor mutational burden (TMB) score, and the survival time of the patients with a low TMB was significantly higher than that of the high-risk group. The risk scores were significantly lower in patients who responded to immunotherapy (complete response/partial response – CR/PR) than in patients who did not respond to immunotherapy (stable disease/progressive disease – SD/PD).

Conclusions
We developed and validated an inflammatory risk model, which served as an independent prognostic indicator and reflected immune response intensity in the BC microenvironment.

keywords:

breast cancer, inflammation response, tumor microenvironment, inflammatory risk model, immune, prognosis

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.